Smoldering Multiple Myeloma Prognosis

Determine risk of progression to symptomatic multiple myeloma.

The global unit selector only affects unanswered questions
1.Bone Marrow Plasmacytosis?
2.M-Protein Size?
Created by

1. Bone Marrow Plasmacytosis?

Created by
0/2 completed

About this Calculator

Smoldering or asymptomatic multiple myeloma (SMM) is a plasma cell dyscrasia characterized by a serum monoclonal protein level of 30 g/L or more or a proportion of plasma cells in the bone marrow of 10% or more but no evidence of end-organ damage. Individuals with SMM have a high-risk of progression to future symptomatic multiple myeloma or amyloidosis. A study from the Mayo Clinic followed 276 patients with SMM over a 26-year study period to establish prognostic factors for progression. The risk of progression was not constant over time. The overall risk of progression was 10% per year for the first 5 years, approximately 3 % per year for the next 5 years, and 1% per year for the last 10 years; the cumulative probability of progression was 73% at 15 years. The proportion of plasma cells in the bone marrow and the serum monoclonal protein concentration were combined to create a risk-stratification model with three distinct prognostic groups.

References

Kyle et al.

Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

New England Journal of Medicine 2007 June 21, 356 (25): 2582-90

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.